Novo Nordisk CEO: Oral Semaglutide Launch In 2020, Novel Obesity Drugs Sought
Novo Nordisk's GLP-1 franchise is advancing strongly and will be reinforced later this year by the expected approval of the ground-breaking oral semaglutide diabetes therapy, said CEO Lars Fruergaard Jørgensen
You may also be interested in...
At the ADA annual meeting, Lilly reported positive results from REWIND, a cardiovascular outcomes trial studying the GLP-1 agonist Trulicity in a broad population of patients with and without established CV disease.
Now that AbiVax's novel anti-inflammatory ABX464 has demonstrated solid safety and efficacy in rheumatoid arthritis and ulcerative colitis, the French biotech is exploring additional programs in chronic inflammatory indications – and looking for a partner.
Arrowhead and Horizon Therapeutics have inked a deal to develop an investigational RNA interference therapy for uncontrolled gout, under which Arrowhead stands to get $40m upfront and up to $660m in milestones.